Suven Pharmaceuticals Ltd
NSE:SUVENPHAR
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
610.45
1 334.2
|
Price Target |
|
We'll email you a reminder when the closing price reaches INR.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one SUVENPHAR stock under the Base Case scenario is 402.41 INR. Compared to the current market price of 1 261.85 INR, Suven Pharmaceuticals Ltd is Overvalued by 68%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
Suven Pharmaceuticals Ltd
Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start backtest now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.
The backtest for SUVENPHAR cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.
Fundamental Analysis
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Revenue & Expenses Breakdown
Suven Pharmaceuticals Ltd
Balance Sheet Decomposition
Suven Pharmaceuticals Ltd
Current Assets | 11.7B |
Cash & Short-Term Investments | 6.7B |
Receivables | 1.9B |
Other Current Assets | 3.1B |
Non-Current Assets | 13.4B |
Long-Term Investments | 1.4B |
PP&E | 8.9B |
Intangibles | 2.7B |
Other Non-Current Assets | 315.9m |
Current Liabilities | 2.4B |
Accounts Payable | 652.8m |
Other Current Liabilities | 1.7B |
Non-Current Liabilities | 2.9B |
Long-Term Debt | 306.6m |
Other Non-Current Liabilities | 2.6B |
Earnings Waterfall
Suven Pharmaceuticals Ltd
Revenue
|
9.6B
INR
|
Cost of Revenue
|
-3.7B
INR
|
Gross Profit
|
5.9B
INR
|
Operating Expenses
|
-3.3B
INR
|
Operating Income
|
2.6B
INR
|
Other Expenses
|
-213.3m
INR
|
Net Income
|
2.4B
INR
|
Free Cash Flow Analysis
Suven Pharmaceuticals Ltd
INR | |
Free Cash Flow | INR |
In Q2 FY '25, Suven Pharma reported a 12% revenue increase to INR 2.58 billion, boosted by the acquisition of Sapala. The pharma CDMO segment surged by 40% year-on-year, with projected full-year growth. Adjusted EBITDA improved to INR 1.11 billion, with margins at 43.3%. Notably, Cohance's performance revealed a 13% decline in revenue, attributed to timing in shipments, but overall growth is anticipated. Suven's commitment to R&D and strategic mergers hints at robust growth, aiming to double the business within five years. Full-year platform growth is expected compared to FY '24, with significant improvements in profitability as well【4:1†source】.
What is Earnings Call?
SUVENPHAR Profitability Score
Profitability Due Diligence
Suven Pharmaceuticals Ltd's profitability score is 62/100. The higher the profitability score, the more profitable the company is.
Score
Suven Pharmaceuticals Ltd's profitability score is 62/100. The higher the profitability score, the more profitable the company is.
SUVENPHAR Solvency Score
Solvency Due Diligence
Suven Pharmaceuticals Ltd's solvency score is 99/100. The higher the solvency score, the more solvent the company is.
Score
Suven Pharmaceuticals Ltd's solvency score is 99/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
SUVENPHAR Price Targets Summary
Suven Pharmaceuticals Ltd
According to Wall Street analysts, the average 1-year price target for SUVENPHAR is 1 356.6 INR with a low forecast of 1 343.3 INR and a high forecast of 1 396.5 INR.
Dividends
Current shareholder yield for SUVENPHAR is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
Ownership
SUVENPHAR Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Profile
Country
Industry
Market Cap
Dividend Yield
Description
Suven Pharmaceuticals Ltd. manufactures chemical products. The company is headquartered in Hyderabad, Telangana and currently employs 1,193 full-time employees. The company went IPO on 2020-03-09. The firm operates through Pharmaceuticals Manufacturing and Services segment. Its geographical segments include India, the United States, Europe and Rest of the World. In India, the Company sells bulk drugs and intermediates, fine chemicals and services. In the United States, the Company sells intermediates and services. In Europe, the Company sells bulk drugs and intermediates. In Rest of the World, the Company sells bulk drugs, intermediates and services. The Company’s wholly owned subsidiary is Suven Pharma Inc.
Contact
IPO
Employees
Officers
The intrinsic value of one SUVENPHAR stock under the Base Case scenario is 402.41 INR.
Compared to the current market price of 1 261.85 INR, Suven Pharmaceuticals Ltd is Overvalued by 68%.